Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohor ...

A breakthrough AI system is revolutionizing cancer immunotherapy by enabling scientists to design protein-based keys that train a patient s immune cells to attack cancer with extreme precision. This ...